Evidence map›Paper›PMID 30344521›Full record

ArticleFrontiers in immunology2018

Dissecting Genetic Control of HLA-DPB1 Expression and Its Relation to Structural Mismatch Models in Hematopoietic Stem Cell Transplantation.

Thuja Meurer, Esteban Arrieta-Bolaños, Maximilian Metzing, Mona-May Langer, Peter van Balen, J H Frederik Falkenburg, Dietrich W Beelen, Peter A Horn, Katharina Fleischhauer, Pietro Crivello

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Role of HLA-DP Expression in Graft-Versus-Host Disease After Unrelated Donor Transplantation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Article
  13. Selection of matched unrelated donors moving forward: from HLA allele counting to functional matching.Hematology. American Society of Hematology. Education Program · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Thuja MeurerInstitute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany.
Esteban Arrieta-BolañosInstitute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany.
Maximilian MetzingInstitute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany.
Mona-May LangerInstitute for Transfusion Medicine, University Hospital Essen, Essen, Germany.
Peter van BalenDepartment of Hematology, Leiden University Medical Center, Leiden, Netherlands.
J H Frederik FalkenburgDepartment of Hematology, Leiden University Medical Center, Leiden, Netherlands.
Dietrich W BeelenDepartment of Bone Marrow Transplantation, West German Cancer Center, University Hospital Essen, Essen, Germany.
Peter A HornInstitute for Transfusion Medicine, University Hospital Essen, Essen, Germany.
Katharina FleischhauerInstitute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany.
Pietro CrivelloInstitute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany.
Essen University Hospital · DELeiden University Medical Center · NLDeutschen Konsortium für Translationale Krebsforschung · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HLA expression levels have been suggested to be genetically controlled by single nucleotide polymorphisms (SNP) in the untranslated regions (UTR), and expression variants have been associated with the outcome of chronic viral infection and hematopoietic stem cell transplantation (HSCT). In particular, the 3'UTR rs9277534-G/A SNP in HLA-DPB1 has been associated with graft-versus-host-disease after HSCT (Expression model); however its relevance in different immune cells and its mode of action have not been systematically addressed. In addition, there is a strong though not complete overlap between the rs9277534-G/A SNP and structural HLA-DPB1 T cell epitope (TCE) groups which have also been associated with HSCT outcome (TCE Structural model). Here we confirm and extend previous findings of significantly higher HLA-DPB1 expression in B cell lines, unstimulated primary B cells, and monocytes homozygous for rs9277534-G compared to those homozygous for rs9277534-A. However, these differences were abrogated by interferon-γ stimulation or differentiation into dendritic cells. We identify at least seven 3'UTR rs9277534-G/A haplotypes differing by a total of 37 SNP, also characterized by linkage to length variants of a short tandem repeat (STR) in intron 2 and TCE group assignment. 3'UTR mapping did not show any significant differences in post-transcriptional regulation assessed by luciferase assays between two representative rs9277534-G/A haplotypes for any of eight overlapping fragments. Moreover, no evidence for alternative splicing associated with the intron 2 STR was obtained by RT-PCR. In an exemplary cohort of 379 HLA-DPB1 mismatched donor-recipient pairs, risk prediction by the Expression model and the Structural TCE model was 36.7% concordant, with the majority of discordances due to non-applicability of the Expression model. HLA-DPB1 from different TCE groups expressed in the absence of the 3'UTR at similar levels by transfected HeLa cells elicited significantly different mean alloreactive CD4+ T-cell responses, as assessed by CD137 upregulation assays in 178 independent cultures. Taken together, our data provide new insights into the cell type-specific and mechanistic basis of the association between the rs9277534-G/A SNP and HLA-DPB1 expression, and show that, despite partial overlap between both models in HSCT risk-prediction, differential alloreactivity determined by the TCE structural model occurs independently from HLA-DPB1 differential expression.

Indexed as

3' Untranslated RegionsAllelesB-LymphocytesCells, CulturedEpitopes, T-LymphocyteGene Expression RegulationGene FrequencyGraft vs Host DiseaseHaplotypesHeLa CellsHematopoietic Stem Cell TransplantationHLA-DP beta-ChainsHumansPolymorphism, Single NucleotideT-Lymphocytes3' Untranslated RegionsEpitopes, T-LymphocyteHLA-DPB1 antigenHLA-DP beta-Chainsexpression levelshematopoietic stem cell transplantationhigh risk non-permissive mismatchesHLA-DPB1rs9277534SNPT cell alloreactivityT cell epitope

Identifiers

PMID30344521
PMCPMC6183238
OpenAlexW2895140305

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.